We are excited to partner with Onduo to bring microlearning patient education into virtual diabetes self-management.
BETHESDA, Md. (PRWEB) January 18, 2018
Mytonomy, a leader in patient experience cloud solutions that leverage behavioral and learning science to drive better health outcomes, announced it will support Onduo, a joint venture created by Verily (an Alphabet company) and Sanofi. Mytonomy will develop custom microlearning video education for Onduo’s Virtual Diabetes Clinic members, and provide their Patient Experience Cloud, white‐labeled under the Onduo brand, enabling Onduo coaches and members access to a master library of modern microlearning patient education, anytime, anywhere on any mobile device.
“Great content engages all audiences. We are excited to support Onduo by applying our microlearning approach to participant education for virtual diabetes self‐management. Mytonomy’s microlearning approach enables patients to learn about the critical aspects of health management strategies from the comfort of their own home on their preferred mobile device,” said Anjali Kataria, CEO of Mytonomy.
“Traditional forms of classroom style diabetes self‐management education have already shown positive gains in patient motivation, understanding, and better health outcomes. However, in an increasingly mobile world, leveraging novel technologies is necessary to build the future foundations of wellness and new habits in chronic care disease management. These require tailoring, personalizing and modernizing patient education to meet patients where they are today, and to drive optimal engagement levels outside of the hospital and clinic.
“Mytonomy’s Patient Experience Cloud will help educate consumers about innovative coaching platforms like Onduo’s Virtual Diabetes Clinic,” said Vinay Bhargava, Co‐Founder, and President of Mytonomy. “By delivering precise patient education enabled by our APIs, we can make the human interaction between coaches and patients more robust and efficient, allowing more patients to be positively impacted.”
Mytonomy is the leader in Patient Experience Cloud Software for hospitals and providers, and custom microlearning patient education rooted in learning and behavioral science that drives longitudinal patient activation. Mytonomy offers a data-driven personalized patient education, engagement, and experience software platform resulting in unprecedented cost savings and significant improvements in patient outcomes. Our Patient Experience Cloud combined with microlearning video education provides a solution for patients to engage with their patient education on any device at any time and to have a consumer-like experience that is both high-tech and high-touch. Mytonomy’s solutions can be used seamlessly across the care continuum and were designed for maximum flexibility, ease of use, and data sharing throughout the clinical workflow. The company has completed two IRB approved clinical research studies across four clinical sites in diabetes and cardiology with positive results and publications expected in forthcoming academic journals. Mytonomy’s founders are former executives from Google, Oracle, and the FDA. The company is based in Bethesda, MD. For more information, visit http://www.mytonomy.com.
Diabetes is a chronic condition characterized by high blood sugar levels that stem from inappropriate production or use of insulin. In 2014, it was estimated that 29 million Americans[i] and 425 million people worldwide[ii] have diabetes. About 90-95% of these individuals have type 2 diabetes and 29% take some form of insulin[iii]. Despite being provided with effective medications, more than half of them do not meet the recommended targets for glycemic control[iv]. Major contributing factors include challenges with insulin initiation and titration. Owing to the complications associated with diabetes, its total annual cost in the US amounts to $245 billion. Optimizing adherence to diabetes medications is recognized as one of the most effective ways of controlling disease expenditures[v]. The cost saving opportunity in the U.S is estimated to be $4,690 per patient per year[vi]. It has been estimated that the global economic burden of diabetes is U.S. $827 billion. [vii]
 National Diabetes Statistics Report, 2014. (2014). Retrieved August 8, 2016, from ii Roglic, G. (2016). Global report on diabetes. Retrieved August 08, 2016, from iii, [iv],[v],[vi]] National Diabetes Statistics Report, 2014. (2014). Retrieved August 8, 2016, from vii NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4*4 million participants. Lancet 2016; published online April 7. http://dx.doi.org/10.1016/S0140-6736(16)00618-8.